Association between Fluorescent Advanced Glycation End-Products and Vascular Complications in Type 2 Diabetic Patients

Table 1

Clinical and biochemical characteristics of the study participants.

Male Sex (%)
With vascular complication
	Average +/− SD	Average +/− SD	value
Age	51.2 +/− 17.7	59.1 +/− 10.3	0.0164
BMI		30.2 +/− 5.5
Total protein (g/L)	69.8 +/− 6.3	70.6 +/− 4.5	0.5201
Albumin (g/L)	40.5 +/− 7.1	42.3 +/− 2.8	<0.0001
Fructosamine (mol/g)	2.67 +/− 0.41	4.78 +/− 0.77	<0.0001
HbA1c (%)	5.3 +/− 0.43	9.1 +/− 1.1	<0.0001
Total cholesterol (mmol/L)	4.4 +/− 0.82	4.14 +/− 1.04	0.2488
HDL-cholesterol (mmol/L)	1.27 +/− 0.44	1.12 +/− 0.29	0.0771
LDL-cholesterol (mmol/L)	2.82 +/− 0.75	2.50 +/− 0.90	0.1079
Triglycerides (mmol)			0.67
(25–75th percentile)
ApoA (mmol/L)	1.42 +/− 0.37	1.30 +/− 0.22
ApoB (mmol/L)	0.84 +/− 0.16	0.89 +/− 0.25

Study participants are divided into two groups: diabetic (D, ) and nondiabetic (ND, ) patients.